DNA Therapeutics
PrivateLast Round
M&A
Mar 28, 2016
Total Funding Raised
$4M
Company Overview
DNA Therapeutics operates in Healthcare & Life Sciences and is based in France. Its latest recorded funding round was a Series A round in January 2009.
DNA Therapeutics is a biotechnology company that develops targeted drugs for sensitizing resistant cancer to conventional cancer therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DNA Therapeutics Comparables
Compare DNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valerio Therapeutics | 87% | |
| Artios Pharma | 80% | |
| Onco-Innovations | 79% |
For institutional investors. Book with your work email.
DNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Mar 28, 2016 | ||||
| Series A | Jan 29, 2009 | ||||
| Seed | Nov 6, 2008 |
For institutional investors. Book with your work email.
DNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Inserm Transfert | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 32% MoM.
- Apr 17, 2026
Monthly visitors grew 71% MoM, from 308 to 528.
For institutional investors. Book with your work email.
DNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DNA Therapeutics's valuation, stock price, and market status.
Is DNA Therapeutics a public or private company?
DNA Therapeutics is a private company.
What is the current stock price of DNA Therapeutics?
DNA Therapeutics is a private company, so its shares have no public market price. Caplight tracks DNA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DNA Therapeutics worth (valuation)?
Valuation information for DNA Therapeutics is not publicly available.
Can I buy DNA Therapeutics stock?
DNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DNA Therapeutics's last funding round?
DNA Therapeutics's most recent funding round was M&A on March 28, 2016.
Who are the main investors in DNA Therapeutics?
Key investors in DNA Therapeutics include Inserm Transfert.
Will DNA Therapeutics IPO soon?
No public IPO plans have been announced for DNA Therapeutics.
How can I track DNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in DNA Therapeutics's shares on secondary markets.